Literature DB >> 26874839

Sleepwalking.

Valérie Cochen De Cock1,2.   

Abstract

OPINION STATEMENT: Sleepwalking (SW) is a parasomnia, an abnormal behavior occurring during sleep. SW is a non-REM sleep parasomnia, an arousal disorder, like sleep terrors and confusional arousals. SW results from an incomplete arousal from slow-wave sleep, some regions of the cerebral cortex being awake and allowing movement and vision for example and others being asleep, preventing memorization or judgment. Usually, SW is a quiet wandering of a child that occurs rarely (several times a month or a year), requiring no medical advice and treatment. To reassure the family and to secure the environment are the only things to do. However, sometimes, SW can become crippling because of its frequency (several times a week or a night) because of the risks associated with the behavior (going outside, manipulating sharp objects, etc.) or violence (throwing objects, using weapons, etc.) or because of its consequences on everyday quality of life (sleepiness, fatigue, insomnia, anxiety, and depressive symptoms). In these conditions, treatment is required. It first associates sleep hygiene, reduction of alcohol consumption, and interruption of the treatments that could have promoted the episodes and the securing of the environment. The treatment of precipitants inducing sleep fragmentation such as sleep disordered breathing can be beneficial, reducing the number of events. If episodes persist or are too dangerous, medical treatment is needed. No adequate large controlled trial of drugs has yet been conducted in SW so that no medication has been evaluated properly for efficacy or side effects. However, experts in the field use clonazepam. This treatment is in our experience often effective. If inefficacious, antidepressants can also be proposed. Psychotherapy should be associated to improve anxiety and sometimes insomnia. Few published cases have described that deep relaxation, hypnosis, and cognitive behavioral therapy could be effective.

Entities:  

Keywords:  Alcohol consumption; Clonazepam; Quality of life; Sleepwalking; Violence; Z-drugs

Year:  2016        PMID: 26874839     DOI: 10.1007/s11940-015-0388-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  57 in total

1.  Parasomnias: sleepwalking and the law.

Authors:  Mark W. Mahowald; Carlos H. Schenck
Journal:  Sleep Med Rev       Date:  2000-08       Impact factor: 11.609

2.  Dissociated local arousal states underlying essential clinical features of non-rapid eye movement arousal parasomnia: an intracerebral stereo-electroencephalographic study.

Authors:  Michele Terzaghi; Ivana Sartori; Laura Tassi; Valter Rustioni; Paola Proserpio; Giorgio Lorusso; Raffaele Manni; Lino Nobili
Journal:  J Sleep Res       Date:  2012-02-14       Impact factor: 3.981

3.  Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder.

Authors:  Yi-Hang Chiu; Chun-Hsin Chen; Winston W Shen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-10-17       Impact factor: 5.067

4.  Arousal reactions in sleepwalking and night terrors in adults: the role of respiratory events.

Authors:  Fabrice Espa; Yves Dauvilliers; Basile Ondze; Michel Billiard; Alain Besset
Journal:  Sleep       Date:  2002-12       Impact factor: 5.849

5.  Treatment of sleepwalking: a controlled study.

Authors:  W H Reid; I Ahmed; C A Levie
Journal:  Am J Psychother       Date:  1981-01

6.  Objective daytime sleepiness in patients with somnambulism or sleep terrors.

Authors:  Régis Lopez; Isabelle Jaussent; Yves Dauvilliers
Journal:  Neurology       Date:  2014-10-29       Impact factor: 9.910

7.  Prevalence and genetics of sleepwalking: a population-based twin study.

Authors:  C Hublin; J Kaprio; M Partinen; K Heikkilä; M Koskenvuo
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

8.  A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application.

Authors:  Colin A Espie; Simon D Kyle; Chris Williams; Jason C Ong; Neil J Douglas; Peter Hames; June S L Brown
Journal:  Sleep       Date:  2012-06-01       Impact factor: 5.849

9.  A scale for assessing the severity of arousal disorders.

Authors:  Isabelle Arnulf; Bin Zhang; Ginevra Uguccioni; Mathilde Flamand; Alix Noël de Fontréaux; Smaranda Leu-Semenescu; Agnès Brion
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

10.  Diazepam in intractable sleepwalking: a pilot study.

Authors:  W H Reid; E A Haffke; C C Chu
Journal:  Hillside J Clin Psychiatry       Date:  1984
View more
  2 in total

Review 1.  Clonazepam for the management of sleep disorders.

Authors:  Alberto Raggi; Maria Paola Mogavero; Lourdes M DelRosso; Raffaele Ferri
Journal:  Neurol Sci       Date:  2022-09-16       Impact factor: 3.830

Review 2.  Therapeutic Symptomatic Strategies in the Parasomnias.

Authors:  Raffaele Manni; Gianpaolo Toscano; Michele Terzaghi
Journal:  Curr Treat Options Neurol       Date:  2018-06-05       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.